Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2024-01-23 00:00:00 ET · period of report 2024-01-19 · accession 0001140361-24-003554 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-23 | 2024-01-19 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +1,570 | 76.3K | +2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-01-19 | A | A | 1,570 | $0.00 | 76,339 | D | — | — | (F1) Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. (F2) The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities. |